Loading clinical trials...

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Feasibility of Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

NCT05909137•Xinqiao Hospital of Chongqing

View on ClinicalTrials.gov

Summary

Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis. The purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

••Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable
•* ECOG whole body status (performancestatus,PS) level 0 or 1
•* The estimated survival time is more than 12 weeks, 18 \~80 years old
•* Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count \> 1,500/ MCL Heathko-Pilot Oncology Research Fund; ② Platelet \> 50,000/ MCL; ③ Total bilirubin \< 1.5 times of the normal upper limit value; ④AST(SGOT)/ALT(SGPT) \< 2.5 times of the normal upper limit; ⑤ Serum creatinine \< 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range
•* Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug
•* Understand and voluntarily sign written informed consent
•* The investigator judged that the patient had good compliance

Exclusion Criteria

•Malignant pleural/pericardial effusions, previous thoracic radiotherapy or chemotherapy
•Uncontrolled concurrent diseases, including but not limited to symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, liver insufficiency, renal insufficiency, uncontrolled diabetic blood sugar, arrhythmia, mental illness or social condition, etc.
•Pregnant or nursing women
•The patient has no history of intracranial hemorrhage or spinal cord hemorrhage
•HIV-positive patients receiving combination antiretroviral therapy
•Active tuberculosis
•Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
•Prior allogeneic stem cell or solid organ transplantation
•Researchers determine other conditions that may affect the conduct of clinical studies and the determination of their findings

Key Dates

Start Date

February 1, 2026

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

July 14, 2025

Enrollment

ESTIMATED participants

Conditions

ImmunotherapyIntensity Modulated Radiation TherapyRadiotherapyNSCLC

Interventions

IMRT+adjuvant immunotherapy

RADIATION

Contacts

jianguo sun, Phd

CONTACT

023-68774490 sunjg09@aliyun.com

tianxiang cui

CONTACT

8613206196552

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

NCT06719440

GlioblastomaRadiotherapy Side Effect

View study

RECRUITINGNA

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

NCT05689463

Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

Hippotherapy Teenager-pediatric Radiotherapy

A Study of TIL in Advanced Solid Tumors (DFGD)